Q2 2026 13F · SEC CIK 1482416

Sio Capital Management, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $583.5M
Reported positions: 57
Top holdings a year, 3 yrs: +16.6%
Assets under management: $1.3B

Sio Capital Management, LLC is a hedge fund that reported 57 positions worth $583.5M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Anteris Technologies Global (AVR, 9.4%), Cencora Inc Com (COR, 8.4%), Maximus Inc. (MMS, 6.6%). A portfolio copying its top holdings returned 16.6% a year over the last 3 years, against 20.4% for the S&P 500.

Sio Capital Management, LLC holdings largest 50 of 57 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Sio Capital Management, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
AVRAnteris Technologies Global	9.4%	4.3%	5,545,984	+3.0%	$54.6M
CORCencora Inc Com	8.4%	4.6%	173,588	+72.0%	$49.1M
MMSMaximus Inc.	6.6%	7.1%	715,267	-7.0%	$38.5M
ALLOAllogene Therapeutics Inc	4.7%	—	13,323,431	—	$27.7M
GMEDGlobus Med Inc	4.1%	—	301,816	—	$23.8M
GSKGsk PLC	3.9%	3.1%	436,700	+13.2%	$22.9M
TYRATyra Biosciences Inc	3.8%	3.3%	695,315	+14.8%	$22.2M
WAYWaystar Hldg Corp	3.3%	5.7%	925,834	-43.6%	$19.0M
IDYAIdeaya Biosciences Inc	3.1%	—	480,383	—	$17.9M
ORKAOruka Therapeutics Inc	2.9%	0.9%	177,118	+33.7%	$16.9M
CIThe Cigna Group	2.7%	—	57,750	—	$15.9M
SNYNFSanofi SA	2.7%	1.7%	364,200	+52.0%	$15.5M
ICLRIcon PLC	2.6%	4.9%	88,186	-71.2%	$15.3M
VTRSViatris Inc	2.6%	—	954,299	—	$15.2M
CCRNCross Country Healthcare Inc	2.5%	1.5%	1,098,393	+0.0%	$14.5M
RAPPRapport Therapeutics Inc	2.2%	1.7%	307,657	-16.1%	$12.8M
ABTAbbott Laboratories	2.0%	2.8%	128,656	-31.0%	$11.7M
CELCCelcuity Inc	2.0%	3.2%	110,022	-43.2%	$11.5M
ZBHZimmer Hldgs Inc	1.9%	0.8%	131,445	+109.9%	$11.3M
REGNRegeneron Pharmaceuticals	1.9%	—	18,000	—	$11.2M
BMYBristol-Myers Squibb Co Com	1.9%	—	193,500	—	$11.1M
MDTMedtronic PLC	1.9%	—	142,500	—	$11.1M
VIRVir Biotechnology Inc	1.9%	1.9%	1,075,274	-28.2%	$11.0M
SENSSenseonics Hldgs Inc	1.6%	—	1,592,692	—	$9.0M
EYPTEyepoint Pharmaceuticals Inc	1.5%	1.3%	623,130	-13.7%	$8.9M
23256X407Cybin Inc	1.5%	—	1,300,000	—	$8.6M
ANIPAni Pharmaceuticals Inc	1.4%	2.9%	97,305	-63.4%	$8.1M
TARAProtara Therapeutics Inc	1.3%	1.5%	1,921,872	-2.4%	$7.3M
RLMDRelmada Therapeutics Inc	1.2%	1.0%	1,003,562	+4.0%	$6.9M
TNGXTango Therapeutics Inc	1.1%	—	208,500	—	$6.5M
AQSTAquestive Therapeutics Inc	1.1%	1.1%	1,486,175	-22.7%	$6.2M
DNTHDianthus Therapeutics Inc	1.0%	4.5%	59,254	-84.0%	$5.8M
829401108Sionna Therapeutics Inc	1.0%	1.7%	127,808	-56.6%	$5.6M
OCULOcular Therapeutix Inc	0.9%	1.2%	539,493	-44.3%	$5.3M
ZBIOZenas Biopharma Inc	0.9%	0.9%	208,557	-37.1%	$5.3M
10919W405Bright Minds Biosciences Inc	0.9%	0.9%	73,952	-14.1%	$5.2M
OKUROnkure Therapeutics Inc	0.8%	0.6%	1,078,965	+0.0%	$4.9M
SVRASavara Inc	0.7%	0.5%	617,675	+0.6%	$3.8M
PMVPPmv Pharmaceuticals Inc	0.6%	0.6%	2,634,137	-14.4%	$3.5M
AVAHAveanna Healthcare Holdings Inc.	0.5%	—	369,036	—	$3.2M
OVIDOvid Therapeutics Inc	0.5%	0.4%	1,005,334	-19.7%	$2.7M
IMNMImmunome Inc	0.5%	0.5%	124,168	-24.8%	$2.6M
ANTXAn2 Therapeutics Inc	0.4%	—	529,933	—	$2.6M
SERSerina Therapeutics Inc	0.3%	—	1,000,000	—	$1.9M
ALGSAligos Therapeutics Inc	0.3%	—	327,237	—	$1.9M
IBIOIbio Inc	0.3%	—	904,268	—	$1.6M
XLOXilio Therapeutics Inc	0.3%	—	152,464	—	$1.5M
AORTArtivion Inc	0.2%	—	48,481	—	$1.1M
BBOTBridgebio Oncology Therapeut	0.2%	—	130,628	—	$995K
TELATela Bio Inc	0.1%	—	636,300	—	$477K

What Sio Capital Management, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +67.5% /yr; S&P 500 +20.1%
3 years: +16.6% /yr; S&P 500 +20.4%
5 years: +7.7% /yr; S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$583.5M	57
Q1 2026	$693.9M	73
Q4 2025	$603.2M	65
Q3 2025	$395.2M	51
Q2 2025	$249.2M	49
Q1 2025	$330.2M	53
Q4 2024	$355.4M	51
Q3 2024	$223.2M	38
Q2 2024	$265.2M	46
Q1 2024	$287.1M	48
Q4 2023	$388.4M	39
Q3 2023	$323.1M	52

Questions about Sio Capital Management, LLC's portfolio

What stocks does Sio Capital Management, LLC own?

Sio Capital Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 57 positions worth $583.5M. The largest are Anteris Technologies Global (AVR) at 9.4%, Cencora Inc Com (COR) at 8.4%, Maximus Inc. (MMS) at 6.6%, Allogene Therapeutics Inc (ALLO) at 4.7% and Globus Med Inc (GMED) at 4.1%.

What did Sio Capital Management, LLC buy last quarter?

In Q2 2026, Sio Capital Management, LLC added Zimmer Hldgs Inc (ZBH) (+109.9% shares), Cencora Inc Com (COR) (+72.0% shares) and Sanofi SA (SNYNF) (+52.0% shares), compared with its Q1 2026 filing.

What did Sio Capital Management, LLC sell last quarter?

In Q2 2026, Sio Capital Management, LLC cut from its top 50 Corcept Therapeutics Inc Com (CORT), cut from its top 50 Livanova PLC (LIVN), cut from its top 50 Embecta Corporation (EMBC), cut from its top 50 Abivax SA (ABVX), cut from its top 50 Haemonetics Corp (HAE), Dianthus Therapeutics Inc (DNTH) (-84.0% shares), Icon PLC (ICLR) (-71.2% shares) and Ani Pharmaceuticals Inc (ANIP) (-63.4% shares), compared with its Q1 2026 filing.

How has Sio Capital Management, LLC's portfolio performed?

A portfolio copying Sio Capital Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +16.6% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +67.5% against +20.1%. Over 5 years: +7.7% a year against +11.6%.

When is Sio Capital Management, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Sio Capital Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Sio Capital Management, LLC manage?

Sio Capital Management, LLC reported $1.3B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $583.5M.